ATX-GD-59, as a pharmaceutical peptide, is a peptide-based therapy (peptide therapy). The main biological mechanism is to imitate epitopes to inactivate leukocytes that attack the thyroid, and prevent anti-thyroid stimulating hormone receptor (TSHR) stimulating antibodies. The immunological basis that can target Graves' disease is expected to become the first modified and innovative therapy for Graves' disease in 60 years. Clinically, ATX-GD-59 has good safety and tolerability in the treatment of Graves' disease, and it can even have normal thyroid stimulating hormone receptor (TSHR) antibody levels.